Our
Research
One of the greatest challenges that we face in discovering new disease therapies is that most proteins are considered “undruggable.” Our research group is reimagining druggability by using chemoproteomic approaches to tackle the undruggable proteome.
Featured Publications
Discovery of a functional covalent ligand targeting an intrinsically disordered cysteine within MYC
Boike L*, Cioffi AG*, Majewski FC, Co J, Henning NJ, Jones MD, Liu G, McKenna JM, Tallarico JA, Schirle M, Nomura DK.
Cell Chemical Biology, 2021, 28, 4-13. PMID 32966806 (*co-first authorship) (Novartis-Berkeley Center for Proteomics and Chemistry Technologies paper)
Manumycin polyketides act as molecular glues between UBR7 and P53
Isobe Y, Okumura M, White R, McGregor LM, Brittain SM, Jones MD, Liang X, White R, Forrester W, McKenna JM, Tallarico JA, Schirle M, Maimone TJ*, Nomura DK*
Nature Chemical Biology, 2020, 16, 1189-1198. PMID 32572277 (*co-corresponding author) (Novartis-Berkeley Center for Proteomics and Chemistry Technologies paper)
Harnessing the anti-cancer natural product nimbolide for targeted protein degradation
Spradlin JN, Hu X, Ward CC, Brittain SM, Jones MD, Ou L, To M, Proudfoot A, Ornelas E, Woldegiorgis M, Olzmann JA, Bussiere DE, Thomas JR, Tallarico JA, McKenna JM, Schirle M, Maimone TJ*, Nomura DK*
Nature Chemical Biology, 2019, 15, 747-755. PMID 31209351 (*co-corresponding authors) (Novartis-Berkeley Center for Proteomics and Chemistry Technologies paper)
Congrats to Mai Luo for starting his position as an Assistant Professor at China Agricultural University
Congrats to Mai Luo and Jessica Spradlin for their Cell Chemical Biology paper on a fully synthetic RNF114 ligand for targeted protein degradation applications!
Congrats to Jessica Spradlin for graduating with her PhD from our lab and the chemistry/chemical biology program!
Our work on SARS-CoV-2 and our recent MYC inhibitor story highlighted by Mark Foundation for Cancer Research
Latest
Tweets
Follow us on Twitter @DanNomura
